Federal prosecutors say a massive COVID-19 test kit billing scheme resulted in approximately $136 million in Medicare payments for products beneficiaries never requested or received.
DES PLAINES, IL – October 30, 2026 (STL.News) An Indian national residing in Illinois has pleaded guilty to participating in a $227 million Medicare fraud scheme involving fraudulent claims for COVID-19 test kits that beneficiaries never requested or received, according to an announcement issued Friday by the U.S. Department of Justice.
Syed Murtuza Kablazada, 36, of Des Plaines, Illinois, pleaded guilty to two counts of health care fraud in connection with an operation involving three Chicago-area laboratories and personal information belonging to hundreds of thousands of Medicare beneficiaries.
According to federal prosecutors, the laboratories submitted approximately $227 million in fraudulent Medicare claims, resulting in approximately $136 million in payments from the federal health insurance program.
The operation involved purchasing Medicare beneficiary information from a purported telemarketing company based in Pakistan, submitting false claims for COVID-19 test kits, and transferring proceeds through financial arrangements intended to conceal the participants’ involvement.
As part of his plea agreement, Kablazada agreed to forfeit more than $46 million in fraud proceeds that federal law enforcement authorities had seized from ten bank accounts.
The guilty plea marks a significant development in a federal prosecution that began with criminal charges announced in May 2025.
The case illustrates how fraudulent operators can exploit medical billing systems to obtain substantial government payments without delivering the products for which reimbursement is requested.
How the $227 Million Medicare Fraud Scheme Operated
According to the Justice Department, Kablazada and his co-schemers acquired three Chicago-area laboratories over approximately six months beginning in January 2023.
The laboratories were identified as Chicago Care, V Care, and Al-Ameer.
After acquiring the laboratories, Kablazada paid approximately $11 million to a purported telemarketing company based in Pakistan to obtain personally identifiable information associated with hundreds of thousands of Medicare beneficiaries.
They then used that information to submit Medicare reimbursement claims for over-the-counter COVID-19 test kits.
However, the beneficiaries had not requested the products, and the test kits were never shipped.
The laboratories submitted approximately $227 million in false and fraudulent claims to Medicare.
Of that amount, Medicare paid approximately $136 million.
The distinction between the amount billed and the amount paid is essential to understanding the financial scope of the case.
The $227 million represents fraudulent claims submitted to Medicare, while the $136 million represents the approximate amount the government program actually disbursed.
The difference between those figures should not be characterized as recovered funds or additional financial losses without supporting documentation.
Federal prosecutors established that the operation used legitimate Medicare beneficiary information to create fraudulent billing transactions through laboratories under the participants’ control.
The claims represented transactions involving covered products, even though the products had not been requested or delivered.
The result was an operation that generated substantial payments from a taxpayer-supported health insurance program.
Medicare Beneficiary Information Was Purchased Overseas
One of the most significant aspects of the case involves the acquisition of personal information belonging to Medicare beneficiaries.
According to the Justice Department, Kablazada paid about $11 million to a purported telemarketing company based in Pakistan for information on hundreds of thousands of individuals.
Federal prosecutors said the information was used to submit fraudulent Medicare claims through the three laboratories.
The October 30 announcement does not explain precisely how the telemarketing company originally obtained the beneficiary information.
Consequently, it would be inaccurate to claim that all the information came from a particular data breach, hacking operation, or other specific method.
The Justice Department established that Kablazada purchased the information and used it to facilitate fraudulent Medicare billing.
The beneficiaries did not request the COVID-19 test kits identified in the claims.
The products were not shipped to them.
This aspect of the prosecution demonstrates how personal information can become a valuable resource for individuals attempting to exploit federal health care reimbursement systems.
Medicare billing depends on information identifying beneficiaries, providers, and covered products or services.
When that information is misused, fraudulent operators can attempt to create transactions that appear to qualify for reimbursement.
The Kablazada case provides a documented example of how such activity can result in substantial improper payments.
It also highlights the importance of protecting beneficiary information and identifying suspicious billing patterns.
Fraud Proceeds Were Transferred Through Financial Networks
The Justice Department reported that Kablazada and his co-schemers used overseas money transfers and unlicensed money transmitters to pay themselves and conceal their involvement.
Federal prosecutors also reported that some of the proceeds were used to purchase luxury vehicles.
These transactions were part of the financial activity associated with the fraudulent scheme.
As the investigation progressed, law enforcement authorities seized fraud proceeds from ten bank accounts.
Under the terms of his plea agreement, Kablazada agreed to forfeit more than $46 million of those proceeds.
The forfeiture represents a substantial financial consequence of the prosecution.
However, the amount agreed to be forfeited should not be confused with the approximately $136 million Medicare paid on the fraudulent claims.
The Justice Department’s October 30 announcement does not establish that the government has recovered the entire amount paid.
It also does not provide a complete accounting of all potential financial recoveries associated with the case.
The use of international transfers and unlicensed money transmitters shows how major fraud schemes can involve financial activity beyond the original billing transactions.
Investigators must often examine not only how fraudulent payments were obtained but also how the proceeds were transferred, concealed, or spent.
In this case, federal authorities identified the movement of money as part of the conduct used to conceal the participants’ involvement.
Federal Charges Were Announced in May 2025
The October 2026 guilty plea follows an earlier Justice Department announcement issued May 22, 2025.
At that time, federal prosecutors announced criminal charges against Kablazada and Syed Mehdi Hussain, then identified as a 32-year-old resident of Carol Stream, Illinois.
The original indictment alleged that the defendants owned and operated purported medical laboratories that submitted fraudulent Medicare claims for COVID-19 test kits.
According to the 2025 announcement, prosecutors alleged that the defendants installed foreign nationals as nominee owners of laboratories to conceal the identities of individuals actually controlling the businesses.
The government further alleged that those nominee owners were expected to leave the United States if they learned that a laboratory was under investigation.
Those statements were allegations in the original indictment announcement and should be distinguished from the conduct established through Kablazada’s subsequent guilty plea.
The May 2025 announcement also alleged that the laboratories rarely provided the COVID-19 test kits for which they requested reimbursement.
Federal prosecutors alleged that claims were submitted using information belonging to beneficiaries who had not requested the products, including individuals who were deceased.
The original announcement described fraudulent billing activity occurring between September 2022 and June 2023.
The October 2026 guilty-plea announcement separately described the acquisition of three laboratories over approximately six months beginning in January 2023.
These statements describe different aspects of the broader investigation and should not be interpreted as identical timelines.
The original indictment charged both Kablazada and Hussain with four counts of health care fraud.
Kablazada has now pleaded guilty to two counts.
The October 30 Justice Department announcement does not provide an updated disposition of the charges against Hussain.
Accordingly, no conclusion about Hussain’s guilt or the current status of his prosecution should be drawn from Kablazada’s guilty plea.
An indictment is an allegation. A defendant who has not been convicted remains presumed innocent unless and until proven guilty beyond a reasonable doubt.
Medicare Fraud Raises Questions About Payment Oversight
The financial scale of this case illustrates a continuing challenge for federal health care programs.
Medicare processes claims from medical professionals, laboratories, facilities, and suppliers providing covered services and products to eligible beneficiaries.
The program must reimburse legitimate claims while identifying fraudulent or otherwise improper billing.
That responsibility becomes particularly complicated when individuals submit claims through businesses that can participate in federal health care reimbursement programs.
In the Kablazada case, federal prosecutors established that three laboratories submitted fraudulent claims for COVID-19 test kits that beneficiaries had not requested or received.
Those claims resulted in approximately $136 million in Medicare payments.
This raises an important public-policy question: How can reimbursement systems identify and interrupt suspicious billing before improper payments reach such substantial amounts?
The Justice Department’s announcement does not identify the specific administrative procedures or payment controls used to process these claims.
It also does not establish that a particular Medicare employee, contractor, or administrator engaged in wrongdoing.
Nevertheless, the documented scale of the fraudulent payments provides a legitimate basis for examining the effectiveness of fraud prevention and detection systems.
Potential areas of examination include provider enrollment procedures, unusual billing volumes, beneficiary verification, and payment monitoring.
These are subjects for broader program-integrity analysis, not specific administrative failures established by the criminal prosecution.
The distinction is important because proving that a criminal scheme succeeded does not, by itself, establish misconduct by the government personnel responsible for administering the program.
The public interest lies in understanding both how the fraudulent operation functioned and what safeguards may reduce the risk of similar schemes.
Taxpayer-Funded Health Programs Face Financial Risks
Medicare is a federal health insurance program serving Americans primarily age 65 and older, along with certain younger individuals who qualify under federal eligibility requirements.
The program is supported through several funding mechanisms, including payroll taxes, beneficiary premiums, and general federal revenues.
Fraudulent claims can therefore affect resources for a program that serves millions of Americans.
The Kablazada prosecution illustrates the financial consequences of submitting claims for products that were never supplied.
In legitimate transactions, Medicare reimbursement supports covered medical care, services, and products.
In this case, prosecutors established that the claims were fraudulent because the beneficiaries had not requested the COVID-19 test kits and the products were never shipped.
The operation did not simply involve a disagreement over reimbursement rates or an administrative billing mistake.
It involved a criminal scheme to obtain payments through false claims.
That distinction is central to understanding the prosecution.
The case should not be interpreted as evidence that medical laboratories generally engage in fraudulent billing.
Instead, it demonstrates how specific individuals used medical billing entities to exploit a federal reimbursement program.
The prosecution also highlights the importance of protecting beneficiary information, maintaining effective provider oversight, and detecting suspicious claims.
Those issues extend beyond COVID-19 testing and apply more broadly to government-funded health care programs.
FBI and Federal Health Investigators Led the Case
The FBI Chicago Field Office and the Department of Health and Human Services Office of Inspector General conducted the investigation.
The Justice Department’s October 30 announcement identified Assistant Attorney General Colin M. McDonald of the National Fraud Enforcement Division, FBI Chicago Special Agent in Charge Ryan Whalen, and HHS-OIG Special Agent in Charge Thomas Ethridge as officials announcing the guilty plea.
Deputy Chief Patrick Mott and Trial Attorney Claire Sobczak Pacelli of the Fraud Division’s Health Care Fraud Section are prosecuting the case.
Assistant U.S. Attorney Andres Almendarez for the Northern District of Illinois assisted in the investigation and prosecution.
The participation of multiple federal agencies reflects the financial and administrative complexity of investigating major health care fraud operations.
Investigations of this type may involve billing records, financial transactions, business ownership information, beneficiary data, and evidence concerning whether billed products or services were actually provided.
The Justice Department also connected the case to its broader fraud enforcement efforts.
According to the October 30 announcement, the department established its Fraud Division on April 7, 2026, to strengthen efforts to investigate and prosecute fraud.
The department stated that its enforcement activities support the Trump administration’s Task Force to Eliminate Fraud, chaired by Vice President J.D. Vance.
The Justice Department also reported that its Health Care Fraud Strike Force Program consists of nine strike forces operating in federal districts across the country.
Since 2007, the program has charged more than 6,200 defendants who collectively billed federal health care programs and private insurers more than $45 billion, according to the department.
That $45 billion represents billing associated with defendants charged through the program. It should not be interpreted as an amount entirely paid by insurers or recovered by federal authorities.
The department also identified the Centers for Medicare & Medicaid Services and HHS-OIG as agencies involved in efforts to hold providers accountable for health care fraud.
Kablazada Faces Up to 20 Years in Prison
Kablazada pleaded guilty to two counts of health care fraud.
According to the Justice Department’s October 30 announcement, he faces a maximum penalty of 20 years in federal prison.
The department stated that sentencing will occur at a later date.
A federal district court judge will determine the sentence after considering the U.S. Sentencing Guidelines and other applicable statutory factors.
The maximum possible penalty does not necessarily represent the sentence Kablazada will ultimately receive.
His agreement to forfeit more than $46 million in seized fraud proceeds is a separate financial consequence of the plea agreement.
Additional developments concerning sentencing, financial recovery, or related proceedings will depend on subsequent court actions and official announcements.
A Significant Case in Federal Medicare Fraud Enforcement
The guilty plea represents a major development in a prosecution involving approximately $227 million in fraudulent Medicare claims and $136 million in payments.
The operation combined several elements of organized financial crime: control of medical billing entities, acquisition of personal information, submission of false claims, and movement of proceeds through financial arrangements intended to conceal the participants’ involvement.
The scale of the operation demonstrates how fraudulent billing can produce substantial financial losses when criminal participants gain access to reimbursement systems.
It also illustrates the importance of distinguishing the amount billed from the amount paid, criminal allegations from admitted conduct, and seized proceeds from total financial losses.
Those distinctions are essential to accurately reporting major federal fraud prosecutions.
For taxpayers, the case raises broader questions about protecting public funds and the effectiveness of systems designed to prevent improper payments.
For Medicare beneficiaries, it illustrates the risks associated with unauthorized use of personal information.
For federal law enforcement authorities, the guilty plea represents an important step toward criminal accountability.
The prosecution also demonstrates that investigating and recovering proceeds from major health care fraud schemes can involve extensive financial tracing and coordination among federal agencies.
As the case proceeds toward sentencing, Kablazada’s guilty plea establishes his criminal responsibility for the conduct admitted in the proceeding.
The ultimate sentence and any additional financial recovery remain subject to subsequent developments.
The broader public-policy issue is whether government health care programs can better identify fraudulent claims before making substantial payments.
The Kablazada prosecution provides a documented example of why that question deserves continued attention.
Sources: U.S. Department of Justice, Office of Public Affairs, Release No. 26-1302, Indian National Pleads Guilty to $227M Medicare Fraud, October 30, 2026; and Release No. 25-540, Two Charged in $227M Medicare Fraud Scheme, May 22, 2025. The court distinguishes earlier indictment allegations from the conduct established through Kablazada’s guilty plea. The court presents discussion of Medicare oversight and program integrity as analysis rather than findings of misconduct by program administrators.
